ReviewFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Lactylation Modification and Esophageal Cancer: Research Progress From Hypoxia-Induced Metabolic Reprogramming to Immune Escape.
Review in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer is a common malignancy of the digestive tract, marked by aggressive invasion, unfavorable prognosis, and limited responsiveness to existing therapeutic strategies. Hypoxia-driven metabolic remodeling represents a key feature of the esophageal cancer microenvironment. In this context, enhanced glycolytic activity leads to lactate accumulation, thereby providing the metabolic substrate for lactylation. Lactylation, a recently recognized lysine post-translational modification, has been detected on both histone and non-histone proteins and regulates tumor biology by modulating chromatin accessibility, gene transcription, protein stability, and signaling pathway activity. Emerging evidence suggests that lactylation is closely involved in the malignant progression of esophageal cancer, including tumor cell proliferation, invasion, stemness maintenance, regulation of programmed cell death, immune escape, and treatment resistance. Under hypoxic conditions, increased lactate production may drive histone lactylation, including histone lactylation marks such as H3K9la, H3K18la, and H4K12la, as well as lactylation of non-histone proteins. These modifications contribute to remodeling of the immunosuppressive tumor microenvironment and weaken anti-tumor immune responses. This review highlights the biological basis of lactate metabolism and lactylation, focusing on their roles in metabolic reprogramming driven by hypoxia, the advancement of tumors, the regulation of the immune microenvironment, immune evasion, and resistance to therapy in esophageal cancer. Additionally, we explore the potential clinical significance of molecules associated with lactylation as diagnostic markers and therapeutic targets, offering fresh insights for precision treatment strategies in esophageal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.